Bernat Olle

5.1k total citations · 1 hit paper
17 papers, 570 citations indexed

About

Bernat Olle is a scholar working on Infectious Diseases, Molecular Biology and Pharmacology. According to data from OpenAlex, Bernat Olle has authored 17 papers receiving a total of 570 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Infectious Diseases, 11 papers in Molecular Biology and 4 papers in Pharmacology. Recurrent topics in Bernat Olle's work include Clostridium difficile and Clostridium perfringens research (14 papers), Gut microbiota and health (11 papers) and Pharmacological Effects of Natural Compounds (4 papers). Bernat Olle is often cited by papers focused on Clostridium difficile and Clostridium perfringens research (14 papers), Gut microbiota and health (11 papers) and Pharmacological Effects of Natural Compounds (4 papers). Bernat Olle collaborates with scholars based in United States, Netherlands and Japan. Bernat Olle's co-authors include Vanni Bucci, Jason M. Norman, Takeshi Tanoue, Richard R. Stein, Kenya Honda, Georg K. Gerber, Elijah Bogart, Qing Liu, Luxue Deng and Lynn Bry and has published in prestigious journals such as JAMA, Nature Medicine and Nature Biotechnology.

In The Last Decade

Bernat Olle

16 papers receiving 560 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

VE303, a Defined Bacterial Consortium, for Prevention of Recurrent Clostridioides difficile Infection

2023 120 citations Thomas Louie, Yoav Golan et al. JAMA profile →

Peers

Countries citing papers authored by Bernat Olle

Since Specialization

Citations

This map shows the geographic impact of Bernat Olle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bernat Olle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bernat Olle more than expected).

Fields of papers citing papers by Bernat Olle

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bernat Olle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bernat Olle. The network helps show where Bernat Olle may publish in the future.

Co-authorship network of co-authors of Bernat Olle

This figure shows the co-authorship network connecting the top 25 collaborators of Bernat Olle. A scholar is included among the top collaborators of Bernat Olle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bernat Olle. Bernat Olle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Multi-omic profiling a defined bacterial consortium for treatment of recurrent Clostridioides difficile infection 2025 ·Nature Medicine ·Rajita Menon, Shakti K. Bhattarai, Emily Crossette, Amanda Prince, Bernat Olle, Jeffrey L. Silber, Vanni Bucci, Jeremiah J. Faith, Jason M. Norman	10
2	607 CONSORTIUM-IO: a phase 1 study evaluating a combination of an 11-strain bacterial consortium (VE800) and nivolumab in treatment of select refractory or metastatic cancers 2024 ·Regular and Young Investigator Award Abstracts ·(unknown), Amanda Prince, (unknown), (unknown), Rajita Menon, Jason M. Norman, Rose L. Szabady, Dmitri Bobilev, (unknown), Jeremiah J. Faith, Jeffrey L. Silber, Bernat Olle, Diwakar Davar	2
3	VE303, a Defined Bacterial Consortium, for Prevention of Recurrent Clostridioides difficile Infection breakdown → 2023 ·JAMA ·Thomas Louie, Yoav Golan, Sahil Khanna, Dmitri Bobilev, Nathalie Erpelding, Candida Fratazzi, (unknown), Rajita Menon, Mary Ruisi, Jason M. Norman, Jeremiah J. Faith, Bernat Olle, (unknown), Jeffrey L. Silber, Darrell S. Pardi	120
4	695 PHARMACODYNAMIC RESPONSE TO A DEFINED BACTERIAL CONSORTIUM, VE303, IN PATIENTS WITH CLOSTRIDIOIDES DIFFICILE INFECTION (CDI): RESULTS OF THE PHASE 2 CONSORTIUM STUDY 2023 ·Gastroenterology ·Rajita Menon, Emily Crossette, Shakti K. Bhattarai, Vanni Bucci, Jeremiah J. Faith, Bernat Olle, Jeffrey L. Silber, Jason M. Norman	1
5	2521. VE707, a Defined Live Biotherapeutic Product for Prevention of Infection by Multidrug-Resistant Gram-Negative Bacteria 2023 ·Open Forum Infectious Diseases ·Gregory L. Medlock, (unknown), (unknown), (unknown), (unknown), Andrea K Watson, (unknown), Jason M. Norman, Jeremiah J. Faith, Ed J. Kuijper, Bernat Olle, Silvia Caballero	4
6	RANDOMIZED, DOUBLE-BLIND, PLACEBO (PBO)-CONTROLLED, SINGLE- AND MULTIPLE-DOSE PHASE 1 STUDY OF VE202, A DEFINED BACTERIAL CONSORTIUM FOR TREATMENT OF IBD: SAFETY AND COLONIZATION DYNAMICS OF A NOVEL LIVE BIOTHERAPEUTIC PRODUCT (LBP) IN HEALTHY ADULTS 2022 ·Inflammatory Bowel Diseases ·Jeffrey H. Silber, Jason M. Norman, Tokuwa Kanno, Emily Crossette, Rose L. Szabady, Rajita Menon, Melissa Marko, Bernat Olle, Esi Lamousé‐Smith	7
7	890: RAPID AND DURABLE COLONIZATION OF VE303 IN CLOSTRIDIODES DIFFICILE INFECTION (CDI) PATIENTS IS ASSOCIATED WITH CLINICAL EFFICACY: RESULTS OF THE PHASE 2 CONSORTIUM STUDY 2022 ·Gastroenterology ·Rajita Menon, Emily Crossette, Shakti K. Bhattarai, Vanni Bucci, Jeremiah J. Faith, Mary Ruisi, Bernat Olle, Jeffrey L. Silber, Jason M. Norman	1
8	RANDOMIZED, DOUBLE-BLIND, PLACEBO (PBO)-CONTROLLED, SINGLE- AND MULTIPLE-DOSE PHASE 1 STUDY OF VE202, A DEFINED BACTERIAL CONSORTIUM FOR TREATMENT OF IBD: SAFETY AND COLONIZATION DYNAMICS OF A NOVEL LIVE BIOTHERAPEUTIC PRODUCT (LBP) IN HEALTHY ADULTS 2022 ·Gastroenterology ·Jeffrey H. Silber, Jason M. Norman, Tokuwa Kanno, Emily Crossette, Rose L. Szabady, Rajita Menon, Melissa Marko, Bernat Olle, Esi Lamousé‐Smith	7
9	Abstract CT246: Consortium-IO: A safety and efficacy study of VE800 in combination with nivolumab in previously treated patients with select advanced metastatic cancers 2020 ·Cancer Research ·Diwakar Davar, Judy S. Wang, Michael Cecchini, Zev A. Wainberg, Martin Gutierrez, Anita Turk, Rose L. Szabady, Jason M. Norman, Bernat Olle, Bruce Roberts, Dmitri Bobilev	4
10	Opportunities and Challenges in Development of Live Biotherapeutic Products to Fight Infections 2020 ·The Journal of Infectious Diseases ·Quinten R. Ducarmon, Ed J. Kuijper, Bernat Olle	22
11	1953. VE303, a Rationally Designed Bacterial Consortium for Prevention of Recurrent Clostridioides difficile (C. Difficile) infection (rCDI), Stably Restores the Gut Microbiota After Vancomycin (vanco)-Induced Dysbiosis in Adult Healthy Volunteers (HV) 2019 ·Open Forum Infectious Diseases ·Dmitri Bobilev, Shakti K. Bhattarai, Rajita Menon, Brian Klein, (unknown), Bernat Olle, Bruce Roberts, Vanni Bucci, Jason M. Norman	12
12	Mo1955 – Ve303, a Live Biotherapeutic Product for Prevention of Recurrent Clostridioides Difficile (C. Difficile) Infection. Preliminary Results of a Phase 1, Open-Label Healthy Volunteers Study of Oral Ve303 After Vancomycin 2019 ·Gastroenterology ·Dmitri Bobilev, (unknown), Paolo B. DePetrillo, Brian Klein, (unknown), Bernat Olle, Bruce Roberts, Jason M. Norman	3
13	Computer-guided design of optimal microbial consortia for immune system modulation 2018 ·eLife ·Richard R. Stein, Takeshi Tanoue, Rose L. Szabady, Shakti K. Bhattarai, Bernat Olle, Jason M. Norman, Wataru Suda, Kenshiro Oshima, Masahira Hattori, Georg K. Gerber, Chris Sander, Kenya Honda, Vanni Bucci	62
14	Translating microbiome futures 2018 ·Nature Biotechnology ·Gaspar Taroncher‐Oldenburg, Susan Jones, Martin J. Blaser, Richard Bonneau, (unknown), José C. Clemente, Eran Elinav, Elodie Ghedin, Curtis Huttenhower, D. F. Kelly, David J. Kyle, Dan R. Littman, Arpita Maiti, Alexander C. Maue, Bernat Olle, Leopoldo N. Segal, Johan E. T. van Hylckama Vlieg, Jun Wang	22
15	MDSINE: Microbial Dynamical Systems INference Engine for microbiome time-series analyses 2016 ·Genome biology ·Vanni Bucci, Belinda Tzen, Ning Li, (unknown), Takeshi Tanoue, Elijah Bogart, Luxue Deng, Vladimir Yeliseyev, (unknown), Qing Liu, Bernat Olle, Richard R. Stein, Kenya Honda, Lynn Bry, Georg K. Gerber	173
16	FDA's pathway for regulation of FMT: not so fraught 2015 ·Journal of Law and the Biosciences ·(unknown), Bernat Olle	2
17	Medicines from microbiota 2013 ·Nature Biotechnology ·Bernat Olle	118

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact